Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition
The deal “provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages o…
Read More